Compare Abeona Therapeutics Inc (ABEO) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Canadian Natural Resources Ltd. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Canadian Natural Resources Ltd. trades at $42.03 (market cap $84.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 227.2× Abeona Therapeutics Inc's market cap, and Canadian Natural Resources Ltd. pays a 4.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CNQ | |
|---|---|---|
Market Cap | $373.32M | $84.83B |
Sector | Health | Energy |
52-Week High | $7.23 | $50.55 |
52-Week Low | $4.17 | $29.31 |
Enterprise Value | $228.22M | $96.06B |
Dividend Yield | — | 4.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Canadian Natural Resources (CNQ) trades at $40.69, up 2.65% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows attractive valuation metrics with P/E of 11.8 and robust profitability including 24.5% net margin. Technical indicators signal bearish sentiment despite recent price strength, while analyst consensus remains overwhelmingly positive with 75% buy ratings. Recent dividend declarations and strong cash flow generation support shareholder returns.
CNQ presents a compelling value opportunity with solid fundamentals and positive earnings surprises, though technical weakness and oil price volatility pose near-term risks. The company's strong balance sheet and consistent dividend payments provide downside protection, while operational efficiency and production growth drive long-term potential. Investors should weigh valuation appeal against energy sector cyclicality and technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
